Systemic sclerosis (scleroderma) trials in United Kingdom

In United Kingdom 12 Also abroad 213

12 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
A Study of AZD0120 in Autoimmune Diseases
Where
Edinburgh, London
Age
18 years to 75 years
People
27 worldwide
Run by
AstraZeneca
See details and how to joinNCT07295847
Phase 3Taking people
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
Where
Cambridge, Leeds, London, Newcastle upon Tyne, Sheffield
Age
5 years to 80 years
People
1,072 worldwide
Run by
AstraZeneca
See details and how to joinNCT07691970
Phase 1/2Taking people
Controlling Hyperactive Immunity With Long-lived Lymphocytes
Where
Birmingham, Leeds, London, Manchester, Newcastle, Oxford
Age
18 years and over
People
16 worldwide
Run by
Quell Therapeutics Limited
See details and how to joinNCT07473154
Phase 3Taking people
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
Where
Bristol, Leeds, London, Salford
Age
18 years and over
People
448 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07497087 · EU 2025-523884-39-00
Phase 2Taking people
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Where
Coventry, Liverpool, London, Westcliff-on-Sea
Age
18 years and over
People
85 worldwide
Run by
Mediar Therapeutics
See details and how to joinNCT07287670
Phase 3Not yet taking people in United Kingdom
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
Where
Leeds, London, Sheffield
Age
16 years and over
People
92 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07335562 · EU 2025-524337-11-00
Phase 3Taking people
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
Where
Leeds, London
Age
18 years and over
People
514 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06716606
Phase 2/3Taking people
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
Where
Birmingham, Leeds, London, Portsmouth, Wakefield
Age
18 years and over
People
300 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT05878717 · EU 2023-503219-14-01
No phaseTaking people
DERMATOMICS: Identifying Regulators of Skin Homeostasis
Where
Leeds, London
Age
18 years and over
People
500
Run by
Relation Therapeutics
See details and how to joinNCT06894654
Phase 1Taking people
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Where
Cambridge, London, Manchester
Age
12 years to 70 years
People
244 worldwide
Run by
Fate Therapeutics
See details and how to joinNCT06308978
No phaseTaking people
EFESO: Study on Juvenile Onset Eosinophilic Fasciitis
Where
Liverpool, Newcastle upon Tyne
Age
Up to 18 years
People
20 worldwide
Run by
Meyer Children's Hospital IRCCS
See details and how to joinNCT07348263
No phaseEnrolling by invitation
Chest CT Biomarkers as Prognostic Predictors in SSc-ILD
Where
Leeds, London
Age
18 years to 99 years
People
1,000 worldwide
Run by
Royal Brompton & Harefield NHS Foundation Trust
See details and how to joinNCT06472362